Disease · GO_0042060
wound healing
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. wound healing. Diseases, record GO_0042060. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/GO_0042060
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs32
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BECAPLERMIN | CHEMBL1201556 | Protein | Approval | EMA Human Drugs, at withdrawal | 2 | 1 | 1 | Drugs and targets |
| DEXPANTHENOL | CHEMBL1200979 | Small molecule | Approval | TTD | 2 | 1 | 1 | Drugs and targets |
| FIBRINOLYSIN, HUMAN | CHEMBL1201505 | Approval | TTD | 1 | 0 | 0 | Drugs and targets | |
| HYALURONIC ACID | CHEMBL5314376 | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets | |
| OZONE | CHEMBL2447938 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ASCORBIC ACID | CHEMBL196 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NITROGLYCERIN | CHEMBL730 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PERFLUNAFENE | CHEMBL1371129 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FENOFIBRATE | CHEMBL672 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INSULIN HUMAN | CHEMBL1201631 | Protein | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 32
See all 32 drugsTargets21
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRB1 | Beta-1 adrenergic receptor | 2 | Beta-1 adrenergic receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/153 | Drugs and targets |
| ADRB2 | Beta-2 adrenergic receptor | 2 | Beta-2 adrenergic receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/154 | Drugs and targets |
| AR | Androgen receptor | 2 | Androgen Receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/367 | Drugs and targets |
| ESR1 | Estrogen receptor | 1 | Estrogen receptor alpha agonist | Phase 2 | https://conductscience.org/library/genes/2099 | Drugs and targets |
| FGA | Fibrinogen | 1 | Fibrinogen inhibitor | Approval | https://conductscience.org/library/genes/2243 | Drugs and targets |
| FGB | Fibrinogen | 1 | Fibrinogen inhibitor | Approval | https://conductscience.org/library/genes/2244 | Drugs and targets |
| FGG | Fibrinogen | 1 | Fibrinogen inhibitor | Approval | https://conductscience.org/library/genes/2266 | Drugs and targets |
| GHR | Growth hormone receptor | 1 | Growth hormone receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/2690 | Drugs and targets |
| GUCY1A1 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 3 | https://conductscience.org/library/genes/2982 | Drugs and targets |
| GUCY1A2 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 3 | https://conductscience.org/library/genes/2977 | Drugs and targets |
1 to 10 of 21
See all 21 targetsTrials20
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00673309 | Assessment of Mechanisms of Improved Wound Healing | Phase 2/3 | 644 | 2019-12-16 | Burns | FENOFIBRATE, INSULIN HUMAN, KETOCONAZOLE, MECASERMIN, NANDROLONE, OXANDROLONE, PRASTERONE, PROPRANOLOL, SOMATROPIN, TESTOSTERONE | Its record names the disease | ClinicalTrials.gov |
| NCT03346902 | Study of EB-001 in Facial Scar Reduction | Phase 2 | 12 | 2018-12-14 | Mohs Surgery | SODIUM CHLORIDE, TRENIBOTULINUMTOXINE | Its record names the disease | ClinicalTrials.gov |
| NCT04234321 | Clinical Study of Kangfuxin and Basic Fibroblast Growth Factor in Promoting the Healing of Donor Site | Not applicable | 300 | Fibroblast Growth Factors, Wound Healing | BASIC FIBROBLAST GROWTH FACTOR (HUMAN) | Its record names the disease | ClinicalTrials.gov | |
| NCT01594775 | Oxytocin, Couple Interaction and Wound Healing | Phase 1 | 160 | Healthy Volunteers | OXYTOCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00847925 | Safety and Efficacy of RN1001(Avotermin) in Healthy Male Subjects | Phase 1/2 | 103 | Cicatrix | AVOTERMIN | Its record names the disease | ClinicalTrials.gov | |
| NCT07064161 | Efficacy of Hydrocolloid Dressing vs. Topical Antibiotic on Wound Healing of Post-Punch Biopsy Wounds | Not applicable | 60 | Biopsy Wound | MUPIROCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT03563625 | Local Wound Infiltration Versus Caudal Block on Wound Infection and Healing in Paediatrics Inguinal Herniotomy | Not applicable | 50 | Healing Surgical Wounds | BUPIVACAINE | Its record names the disease | ClinicalTrials.gov | |
| NCT07234994 | Comparison of the Effect of Ozonized Gel to That of Photobiomodulation Therapy on Wound Healing Following Surgical Gingivectomy | Not applicable | 48 | Gingival Enlargement | OZONE | Its record names the disease | ClinicalTrials.gov | |
| NCT00984386 | Investigation of the Efficacy of Zesteem in Accelerating Early Wound Healing | Phase 2 | 44 | Cicatrix, Wound-healing | ESTRADIOL | Its record names the disease | ClinicalTrials.gov | |
| NCT00978367 | Investigation of the Safety, Dosing Frequency and Anti-Scarring Potential of Two Concentrations of Intradermal Avotermin (Juvista) | Phase 1/2 | 43 | Cicatrix, Wound Healing, Re-epithelialization | AVOTERMIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 20
See all 20 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| EB001 vs Placebo: deaths from any cause | 0 of 8 | 0 of 4 | 12 | NCT03346902 | Trial comparisons |
| EB001 vs Placebo: serious adverse events | 0 of 8 | 0 of 4 | 12 | NCT03346902 | Trial comparisons |
Papers from its trials14
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 37891549 | RESULT | 1 | PubMed |
| 41222549 | DERIVED | 1 | PubMed |
| 40356464 | DERIVED | 1 | PubMed |
| 36656551 | DERIVED | 1 | PubMed |
| 35472193 | DERIVED | 1 | PubMed |
| 23511841 | DERIVED | 1 | PubMed |
| 22606232 | DERIVED | 1 | PubMed |
| 21789167 | DERIVED | 1 | PubMed |
| 20739853 | DERIVED | 1 | PubMed |
| 20701787 | DERIVED | 1 | PubMed |
1 to 10 of 14
See all 14 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/GO_0042060
GET https://conductscience.org/api/diseases/v1/GO_0042060/drugs?page=2